CoChat

VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma

Open access

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Abstract

Little is known about the factors that enable the mobilisation of human mesenchymal stem cells (MSC) from the bone marrow into the blood stream and their recruitment to and retention in the tumour. We found specific migration of MSC towards growth factors present in pancreatic tumours, such as PDGF, EGF, VEGF and specific inhibitors Glivec, Erbitux and Avastin interfered with migration. Within a few hours, MSC migrated into spheroids consisting of pancreatic cancer cells, fibroblasts and endothelial cells as measured by time-lapse microscopy. Supernatant from subconfluent MSC increased sprouting of HUVEC due to VEGF production by MSC itself as demonstrated by RT-PCR and ELISA. Only few MSCs were differentiated into endothelial cells in vitro, whereas in vivo differentiation was not observed. Lentiviral GFP-marked MSCs, injected in nude mice xenografted with orthotopic pancreatic tumours, preferentially migrated into the tumours as observed by FACS analysis of green fluorescent cells. By immunofluorescence and intravital microscopic studies, we found the interaction of MSC with the endothelium of blood vessels. Mesenchymal stem cells supported tumour angiogenesis in vivo, that is CD31(+) vessel density was increased after the transfer of MSC compared with siVEGF-MSC. Our data demonstrate the migration of MSC toward tumour vessels and suggest a supportive role in angiogenesis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjc.6604508

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Migration of MSC to growing tumour and normal cells, VEGF, PDGF, and EGF. (A) Established cell lines from pancreatic cancer (Capan-1, Colo357, BxPc-3, and MIA-PaCa-2), kidney (T293), and primary cell lines from fibroblasts and endothelial cells were cultured in medium containing 2% FCS for 48 h. Supernatant was transferred to the lower well and migration of MSC placed to the upper well was measured in a ChemoTx system as described in Materials and methods. Pos Co, cell-free medium with 20% FCS; Neg Co, cell-free medium with 2% FCS. (B) Dose-dependent migration of MSC towards medium containing 2% FCS alone (CO) or to VEGF, PDGF, and EGF in 2% FCS and in concentrations indicated. (C) Migration of MSC to growth factors alone (GF alone) or to growth factors in the presence of the inhibitor of PDGF receptor (Glivec, 3 μM), or blocking antibodies to EGF receptor (Erbitux, 3 μM), or VEGF (Avastin, 25 μg/ml). (D) Induction of HIF-1α and secretion of VEGF by pancreatic cancer cells following hypoxia. For the induction of hypoxia, the pancreatic cancer cell line BxPc-3 was treated with CoCl2 (100 μM). Two to 16 h later, protein expression of HIF-1α was examined by western blot analysis. β-Actin served as a control for equal conditions. For the evaluation of VEGF secretion, a six-well plate with growing BxPc-3 cells was placed in a modular incubator chamber and hypoxia was induced by floating with a preanalysed air mixture (89.25% N2, 10% CO2, 0.75% O2) at 37°C for 16 h. Immediately thereafter, VEGF secretion into the supernatant was analysed by the ELISA assay, as described in Materials and methods. Results presented are from three independent experiments and s.d. are shown.
Figure 1 Migration of MSC to growing tumour and normal cells, VEGF, PDGF, and EGF. (A) Established cell lines from pancreatic cancer (Capan-1, Colo357, BxPc-3, and MIA-PaCa-2), kidney (T293), and primary cell lines from fibroblasts and endothelial cells were cultured in medium containing 2% FCS for 48 h. Supernatant was transferred to the lower well and migration of MSC placed to the upper well was measured in a ChemoTx system as described in Materials and methods. Pos Co, cell-free medium with 20% FCS; Neg Co, cell-free medium with 2% FCS. (B) Dose-dependent migration of MSC towards medium containing 2% FCS alone (CO) or to VEGF, PDGF, and EGF in 2% FCS and in concentrations indicated. (C) Migration of MSC to growth factors alone (GF alone) or to growth factors in the presence of the inhibitor of PDGF receptor (Glivec, 3 μM), or blocking antibodies to EGF receptor (Erbitux, 3 μM), or VEGF (Avastin, 25 μg/ml). (D) Induction of HIF-1α and secretion of VEGF by pancreatic cancer cells following hypoxia. For the induction of hypoxia, the pancreatic cancer cell line BxPc-3 was treated with CoCl2 (100 μM). Two to 16 h later, protein expression of HIF-1α was examined by western blot analysis. β-Actin served as a control for equal conditions. For the evaluation of VEGF secretion, a six-well plate with growing BxPc-3 cells was placed in a modular incubator chamber and hypoxia was induced by floating with a preanalysed air mixture (89.25% N2, 10% CO2, 0.75% O2) at 37°C for 16 h. Immediately thereafter, VEGF secretion into the supernatant was analysed by the ELISA assay, as described in Materials and methods. Results presented are from three independent experiments and s.d. are shown.CC BY · PubMed Central
Figure 2 Migration of MSC to spheroids of pancreatic tumour cells. (A) Green-labeled spheroids (composed of 5 × 102 MIA-PaCa-2, 2.5 × 102 human primary fibroblasts, and 2.5 × 102 HUVEC) and red-labeled MSC were seeded in opposite edges of a well of a 24-well plate and covered with methocel/collagen solution as described in Materials and methods. (B) Cells were analysed using a fluorescence microscope (Olympus IX 70) with a red and green filter, 20-fold magnification and two-fold binning immediately after seeding. The focus was put to spheroids. Migration of red fluorescent MSC to green fluorescent spheroids was monitored by time-lapse photography during a period of 12 h and a picture was taken every 5 min. Representative data of one experiment out of three similar is shown.
Figure 2 Migration of MSC to spheroids of pancreatic tumour cells. (A) Green-labeled spheroids (composed of 5 × 102 MIA-PaCa-2, 2.5 × 102 human primary fibroblasts, and 2.5 × 102 HUVEC) and red-labeled MSC were seeded in opposite edges of a well of a 24-well plate and covered with methocel/collagen solution as described in Materials and methods. (B) Cells were analysed using a fluorescence microscope (Olympus IX 70) with a red and green filter, 20-fold magnification and two-fold binning immediately after seeding. The focus was put to spheroids. Migration of red fluorescent MSC to green fluorescent spheroids was monitored by time-lapse photography during a period of 12 h and a picture was taken every 5 min. Representative data of one experiment out of three similar is shown.CC BY · PubMed Central
Figure 3 Mesenchymal stem cells induce sprouting of endothelial cells by VEGF expression but do not differentiate into endothelial cells. (A) Vascular endothelial growth factor protein in supernatant of MSC cultured under hypoxic (black bars) or normoxic (white bars) conditions in the presence or absence of Avastin (25 μg ml−1) was analysed by the ELISA assay. (B) RNA expression of VEGF was analysed by RT-PCR in MSC. The expression of α-SMA served as control for equal conditions. (C) A volume of 100 or 200 μl supernatant from MSC (as indicated), which have been cultured in medium containing 2% FCS for 48 h or recombinant VEGF (50 ng ml−1), was transferred to spheroids consisting of 1 × 103 HUVEC growing in wells of a 24-well plate 48 spheroids per well. The length of sprouts was analysed by cellB 2.3 software and median lengths are given. Representative spheroids have been visualised by phase-contrast microscopy using an Olympus CKX41 microscope, × 10 magnification, and a colorview camera soft imaging system. (D) Mesenchymal stem cells were seeded on chamber slights covered with fibronectin and cultured in endothelial cell medium containing VEGF (50 ng ml−1) for 2 weeks. Immunohistochemistry was performed using specific antibodies for the detection of the specific endothelial cell markers von-Willebrand factor (α-vWF) and CD31 (α-CD31). Human umbilical vein endothelial cells were used as positive control. A Leica DMRB microscope and × 1000 magnification were used.
Figure 3 Mesenchymal stem cells induce sprouting of endothelial cells by VEGF expression but do not differentiate into endothelial cells. (A) Vascular endothelial growth factor protein in supernatant of MSC cultured under hypoxic (black bars) or normoxic (white bars) conditions in the presence or absence of Avastin (25 μg ml−1) was analysed by the ELISA assay. (B) RNA expression of VEGF was analysed by RT-PCR in MSC. The expression of α-SMA served as control for equal conditions. (C) A volume of 100 or 200 μl supernatant from MSC (as indicated), which have been cultured in medium containing 2% FCS for 48 h or recombinant VEGF (50 ng ml−1), was transferred to spheroids consisting of 1 × 103 HUVEC growing in wells of a 24-well plate 48 spheroids per well. The length of sprouts was analysed by cellB 2.3 software and median lengths are given. Representative spheroids have been visualised by phase-contrast microscopy using an Olympus CKX41 microscope, × 10 magnification, and a colorview camera soft imaging system. (D) Mesenchymal stem cells were seeded on chamber slights covered with fibronectin and cultured in endothelial cell medium containing VEGF (50 ng ml−1) for 2 weeks. Immunohistochemistry was performed using specific antibodies for the detection of the specific endothelial cell markers von-Willebrand factor (α-vWF) and CD31 (α-CD31). Human umbilical vein endothelial cells were used as positive control. A Leica DMRB microscope and × 1000 magnification were used.CC BY · PubMed Central
Figure 4 Migration of MSC in orthotopic MIA-PaCa-2 pancreatic xenografts in nude mice and the incorporation in tumour blood vessels. (A) Four mice with MIA-PaCa-2 orthotopic pancreatic cancer xenografts were injected with lentiviral eGFP-labeled MSC (4 × 105 in tail vein). Four xenografted mice received PBS injection and served as controls. Three days after injection, mice were killed followed by the resection of organs and xenografts. Cells were isolated from tissue pieces and examined by flow cytometry for expression of green fluorescence of eGFP-expressing MSC. Mean bars±s.e. are shown. (B) Four xenografted mice per group were injected with PBS only (no MSC) or with MSC transduced with lentiviral control vector (VEC-CO), or with MSC transduced with lentiviral siRNA towards VEGF (siVEGF). Three days later, microvessel density in cryosections of xenografts was analysed by immunohistochemistry for CD31 in a Leica DMRB microscope with 250-fold magnification. Microvessel density was quantified using eight images from each of four different tumours per group. Microvessels per field of 1 mm2 were counted. (C) Data from one representative staining per group are shown. (D) Vascular endothelial growth factor protein in supernatant of MSC transduced with lentiviral control vector (VEC-CO) or with siRNA towards VEGF (siVEGF) cultured under normoxic (white bars) or hypoxic (black bars) conditions was analysed by the ELISA assay. Statistical significance was determined by t-test (P<0.05) and is indicated by an asterisk.
Figure 4 Migration of MSC in orthotopic MIA-PaCa-2 pancreatic xenografts in nude mice and the incorporation in tumour blood vessels. (A) Four mice with MIA-PaCa-2 orthotopic pancreatic cancer xenografts were injected with lentiviral eGFP-labeled MSC (4 × 105 in tail vein). Four xenografted mice received PBS injection and served as controls. Three days after injection, mice were killed followed by the resection of organs and xenografts. Cells were isolated from tissue pieces and examined by flow cytometry for expression of green fluorescence of eGFP-expressing MSC. Mean bars±s.e. are shown. (B) Four xenografted mice per group were injected with PBS only (no MSC) or with MSC transduced with lentiviral control vector (VEC-CO), or with MSC transduced with lentiviral siRNA towards VEGF (siVEGF). Three days later, microvessel density in cryosections of xenografts was analysed by immunohistochemistry for CD31 in a Leica DMRB microscope with 250-fold magnification. Microvessel density was quantified using eight images from each of four different tumours per group. Microvessels per field of 1 mm2 were counted. (C) Data from one representative staining per group are shown. (D) Vascular endothelial growth factor protein in supernatant of MSC transduced with lentiviral control vector (VEC-CO) or with siRNA towards VEGF (siVEGF) cultured under normoxic (white bars) or hypoxic (black bars) conditions was analysed by the ELISA assay. Statistical significance was determined by t-test (P<0.05) and is indicated by an asterisk.CC BY · PubMed Central
Figure 5 Recruitment of MSC in mice by intravital microscopy reveals attachment to normal and tumour blood vessels. Mice with MIA-PaCa-2 orthotopic pancreatic cancer xenografts were injected with lentiviral GFP-transduced MSC (four consecutive injections of 105 MSC per 0.2 ml normal saline in time intervals of about 15 min) into the carotid artery. Photographs of circulating MSC in (A) cremaster muscle and (B) tumour vessels were taken and analysed as described in Materials and methods. Circulating (white arrow) and attached (white asterisk) green fluorescent MSC appeared during the first minute after injection. Red arrows indicate the direction of flow. a, artery; v, venule. Pictures are freezed images from video sequences provided in the supplement. (C) Immunofluorescence staining of a GFP-expressing MSC incorporated in vWF-positive endothelial cells of a vessels was detected in an orthotopic pancreatic xenograft of nude mice, which have been injected with MSC as described in Figure 4.
Figure 5 Recruitment of MSC in mice by intravital microscopy reveals attachment to normal and tumour blood vessels. Mice with MIA-PaCa-2 orthotopic pancreatic cancer xenografts were injected with lentiviral GFP-transduced MSC (four consecutive injections of 105 MSC per 0.2 ml normal saline in time intervals of about 15 min) into the carotid artery. Photographs of circulating MSC in (A) cremaster muscle and (B) tumour vessels were taken and analysed as described in Materials and methods. Circulating (white arrow) and attached (white asterisk) green fluorescent MSC appeared during the first minute after injection. Red arrows indicate the direction of flow. a, artery; v, venule. Pictures are freezed images from video sequences provided in the supplement. (C) Immunofluorescence staining of a GFP-expressing MSC incorporated in vWF-positive endothelial cells of a vessels was detected in an orthotopic pancreatic xenograft of nude mice, which have been injected with MSC as described in Figure 4.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 41 references

Cited by

See all 406

Metadata

Authors
Beckermann, B. M., Kallifatidis, G., Groth, A., Frommhold, D., Apel, A., Mattern, J., Salnikov, A. V., Moldenhauer, G., Wagner, W., Diehlmann, A., Saffrich, R., Schubert, M., Ho, A. D., Giese, N., Büchler, M. W., Friess, H., Büchler, P., & Herr, I.
Affiliations
  • German Cancer Research Center (DE)
  • Heidelberg University (DE)
Corresponding author
Herr, I
Venue
British Journal of Cancer
Published
2008-07-29
Volume
99
Issue
4
Pages
622-631
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W2001213911
Cited by
406
References
41
Citations by year
2026: 9 · 2025: 9 · 2024: 19 · 2023: 22 · 2022: 26 · 2021: 28 · 2020: 24 · 2019: 35 · 2018: 25 · 2017: 18 · 2016: 25 · 2015: 24 · 2014: 23 · 2013: 27 · 2012: 21
FWCI
9.73
Type
journal article
Language
en
Open access
Locations
  • British Journal of Cancer (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • mediaTUM (Technical University of Munich) (submittedVersion)
Funders
  • Bundesministerium für Bildung und Forschung
  • Deutsche Krebshilfe
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords
mesenchymal stem cells, vascular endothelial growth factor, tumor angiogenesis, pancreatic cancer, tumor cell migration, tumor microenvironment, platelet-derived growth factor, epidermal growth factor, VEGF inhibitors, endothelial sprouting, tumor vasculature, tumor cell differentiation
MeSH terms
Bevacizumab, Cetuximab, Imatinib Mesylate, Actins, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Benzamides, Cell Differentiation, Cell Movement, Cells, Cultured, Endothelium, Vascular, Epidermal Growth Factor, Fibroblasts, Humans, Male, Mice, Nude, Muscle, Smooth, Neovascularization, Pathologic, Pancreatic Neoplasms, Piperazines, Platelet-Derived Growth Factor, Pyrimidines, Transplantation, Heterologous, Umbilical Veins, Lentivirus, Spheroids, Cellular, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Mesenchymal Stem Cell Transplantation, Cell Proliferation, Mice, Mesenchymal Stem Cells, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. https://app.cochat.ai/papers/10.1038/sj.bjc.6604508
The paper
Beckermann, B. M., Kallifatidis, G., Groth, A., Frommhold, D., Apel, A., Mattern, J., Salnikov, A. V., Moldenhauer, G., Wagner, W., Diehlmann, A., Saffrich, R., Schubert, M., Ho, A. D., Giese, N., Büchler, M. W., Friess, H., Büchler, P., & Herr, I. (2008). VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6604508

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.